A study of the efficacy of milnacipran in patients with major depressive disorder (MDD) after SSRI treatment failure, and biological research for MDD using peripheral blood.

Trial Profile

A study of the efficacy of milnacipran in patients with major depressive disorder (MDD) after SSRI treatment failure, and biological research for MDD using peripheral blood.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Major depressive disorder
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 22 Nov 2013 Results presented at the 13th International Forum on Mood and Anxiety Disorders.
    • 25 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 19 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top